
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
Abraxis backs SPARC as prognostic biomarker
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).
Articles in this issue
almost 17 years ago
ADT in prostate ca increases risk of bone and heart complicationsalmost 17 years ago
ALK-1 receptor: New target in angiogenesisalmost 17 years ago
Abraxane prolongs PFS in metastatic diseasealmost 17 years ago
SAVI applicator removes obstacles associated with brachytherapyalmost 17 years ago
Mistrust, costs reduce breast cancer screening among minoritiesalmost 17 years ago
Oral chemotherapy poses more challenges for cancer communityalmost 17 years ago
CMS nixes CT colonography screeningalmost 17 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































